Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Fuller

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
The Annals of Pharmacotherapy|November 4, 2004
Long-acting injectable risperidoneMegan J Ehret, Matthew A Fuller
The Annals of Pharmacotherapy|November 4, 2004
Duloxetine: a dual reuptake inhibitorSara E Dugan, Matthew A Fuller
The Annals of Pharmacotherapy|July 6, 2012
Dalfampridine: a medication to improve walking in patients with multiple sclerosisTheodore E Pikoulas, Matthew A Fuller
Journal of Pharmacy Practice|December 14, 2011
Asenapine: a new antipsychotic optionJessica M Henry, Matthew A Fuller
Neuropsychiatric Disease and Treatment|May 5, 2009
Risperidone in the treatment of bipolar maniaMartha Sajatovic, Madhusoodanan Subramoniam, Matthew A Fuller
The Annals of Pharmacotherapy|December 29, 2005
Catatonic schizophrenia and the use of memantineStacey S Carpenter, A Daniel Hatchett, Matthew A Fuller
The Mental Health Clinician|May 25, 2019
Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophreniaRobert J Willborn, Colleen P Hall, Matthew A Fuller
Psychiatric Services (Washington, D.C.)|April 7, 2004
Incorporating clinical monitoring into electronic orders for antipsychoticsJennifer Roche-Desilets, Matthew A Fuller, P Eric Konicki
Schizophrenia Research|December 22, 2007
Clozapine: toxicity vs. postmortem redistributionGeorge E Jaskiw, P E Konicki, Matthew A Fuller
Expert Opinion on Drug Safety|June 16, 2006
Practical considerations for carbamazepine use in bipolar disorderMatthew A Fuller, Victor Dostrow, Sanjay Gupta, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The Annals of Pharmacotherapy|November 4, 2004
Long-acting injectable risperidoneMegan J Ehret, Matthew A Fuller
The Annals of Pharmacotherapy|November 4, 2004
Duloxetine: a dual reuptake inhibitorSara E Dugan, Matthew A Fuller
The Annals of Pharmacotherapy|July 6, 2012
Dalfampridine: a medication to improve walking in patients with multiple sclerosisTheodore E Pikoulas, Matthew A Fuller
Journal of Pharmacy Practice|December 14, 2011
Asenapine: a new antipsychotic optionJessica M Henry, Matthew A Fuller
Neuropsychiatric Disease and Treatment|May 5, 2009
Risperidone in the treatment of bipolar maniaMartha Sajatovic, Madhusoodanan Subramoniam, Matthew A Fuller
The Annals of Pharmacotherapy|December 29, 2005
Catatonic schizophrenia and the use of memantineStacey S Carpenter, A Daniel Hatchett, Matthew A Fuller
The Mental Health Clinician|May 25, 2019
Recycling N-acetylcysteine: A review of evidence for adjunctive therapy in schizophreniaRobert J Willborn, Colleen P Hall, Matthew A Fuller
Psychiatric Services (Washington, D.C.)|April 7, 2004
Incorporating clinical monitoring into electronic orders for antipsychoticsJennifer Roche-Desilets, Matthew A Fuller, P Eric Konicki
Schizophrenia Research|December 22, 2007
Clozapine: toxicity vs. postmortem redistributionGeorge E Jaskiw, P E Konicki, Matthew A Fuller
Expert Opinion on Drug Safety|June 16, 2006
Practical considerations for carbamazepine use in bipolar disorderMatthew A Fuller, Victor Dostrow, Sanjay Gupta, et al.
Pageof 3